Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)
Go back to Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 529.59 +1.55 (0.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $528.04 | 52 Week High | $134.71 | |||
| Open | $526.66 | 52 Week Low | $73.31 | |||
| Day High | $529.99 | P/E | N/A | |||
| Day Low | $512.34 | EPS | $-1.98 | |||
| Volume | 1,513,443 | |||||
